ESTA
Establishment Labs·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ESTA
Establishment Labs Holdings Inc.
A medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market
Healthcare Providers and Services
10/09/2013
07/19/2018
NASDAQ Stock Exchange
1,023
12-31
Common stock
11401 Century Oaks Terrace
Suite 400
Austin
Texas 78758
--
Establishment Labs Holdings Inc., was reorganized on October 9, 2013 under the control of the parent company of the British Virgin Islands. The company is a medical technology company dedicated to improving patient safety and aesthetics, initially focusing on the breast aesthetics and reconstruction market. Its silicone filled breast implants under the brand name Motiva Implants are the core product of its medical technology platform. The company has also developed other complementary products and services designed to further improve patient outcomes.
Earnings Call
Company Financials
EPS
ESTA has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.51, beating expectations. The chart below visualizes how ESTA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ESTA has released its 2025 Q3 earnings report, with revenue of 53.78M, reflecting a YoY change of 33.70%, and net profit of -11.15M, showing a YoY change of 33.19%. The Sankey diagram below clearly presents ESTA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available


